Logo image of ANAB

ANAPTYSBIO INC (ANAB) Stock Fundamental Analysis

NASDAQ:ANAB - Nasdaq - US0327241065 - Common Stock - Currency: USD

18.59  -0.28 (-1.48%)

After market: 18.59 0 (0%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to ANAB. ANAB was compared to 572 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ANAB as it has an excellent financial health rating, but there are worries on the profitability. ANAB is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ANAB had negative earnings in the past year.
In the past year ANAB has reported a negative cash flow from operations.
In the past 5 years ANAB always reported negative net income.
ANAB had a negative operating cash flow in each of the past 5 years.
ANAB Yearly Net Income VS EBIT VS OCF VS FCFANAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M

1.2 Ratios

ANAB has a Return On Assets of -33.57%. This is in the better half of the industry: ANAB outperforms 63.41% of its industry peers.
ANAB has a Return On Equity of -196.35%. This is in the lower half of the industry: ANAB underperforms 69.27% of its industry peers.
Industry RankSector Rank
ROA -33.57%
ROE -196.35%
ROIC N/A
ROA(3y)-22.08%
ROA(5y)-18.68%
ROE(3y)-83.68%
ROE(5y)-56.02%
ROIC(3y)N/A
ROIC(5y)N/A
ANAB Yearly ROA, ROE, ROICANAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

ANAB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANAB Yearly Profit, Operating, Gross MarginsANAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600 -800 -1K

More info and screens

8

2. Health

2.1 Basic Checks

ANAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ANAB has been reduced compared to 1 year ago.
ANAB has less shares outstanding than it did 5 years ago.
There is no outstanding debt for ANAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ANAB Yearly Shares OutstandingANAB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
ANAB Yearly Total Debt VS Total AssetsANAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

ANAB has an Altman-Z score of -1.09. This is a bad value and indicates that ANAB is not financially healthy and even has some risk of bankruptcy.
ANAB has a Altman-Z score (-1.09) which is comparable to the rest of the industry.
ANAB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.09
ROIC/WACCN/A
WACC9.44%
ANAB Yearly LT Debt VS Equity VS FCFANAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M

2.3 Liquidity

A Current Ratio of 10.23 indicates that ANAB has no problem at all paying its short term obligations.
ANAB has a better Current ratio (10.23) than 80.46% of its industry peers.
A Quick Ratio of 10.23 indicates that ANAB has no problem at all paying its short term obligations.
ANAB has a better Quick ratio (10.23) than 80.64% of its industry peers.
Industry RankSector Rank
Current Ratio 10.23
Quick Ratio 10.23
ANAB Yearly Current Assets VS Current LiabilitesANAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for ANAB have decreased strongly by -12.18% in the last year.
The Revenue has grown by 282.17% in the past year. This is a very strong growth!
The Revenue has been growing by 27.97% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-12.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.15%
Revenue 1Y (TTM)282.17%
Revenue growth 3Y-38.84%
Revenue growth 5Y27.97%
Sales Q2Q%804.67%

3.2 Future

The Earnings Per Share is expected to decrease by -4.65% on average over the next years.
ANAB is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 50.90% yearly.
EPS Next Y-2.08%
EPS Next 2Y5.22%
EPS Next 3Y4.89%
EPS Next 5Y-4.65%
Revenue Next Year441.71%
Revenue Next 2Y80.81%
Revenue Next 3Y57.97%
Revenue Next 5Y50.9%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ANAB Yearly Revenue VS EstimatesANAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M 500M
ANAB Yearly EPS VS EstimatesANAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ANAB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ANAB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANAB Price Earnings VS Forward Price EarningsANAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANAB Per share dataANAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.22%
EPS Next 3Y4.89%

More info and screens

0

5. Dividend

5.1 Amount

ANAB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANAPTYSBIO INC

NASDAQ:ANAB (2/21/2025, 8:01:11 PM)

After market: 18.59 0 (0%)

18.59

-0.28 (-1.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2024-11-05/amc
Earnings (Next)02-27 2025-02-27/amc
Inst Owners109.28%
Inst Owner Change11.19%
Ins Owners1.86%
Ins Owner Change1.71%
Market Cap565.69M
Analysts82.35
Price Target36.44 (96.02%)
Short Float %21.89%
Short Ratio5.86
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-18.69%
Min EPS beat(2)-69.51%
Max EPS beat(2)32.14%
EPS beat(4)2
Avg EPS beat(4)-9.35%
Min EPS beat(4)-69.51%
Max EPS beat(4)32.14%
EPS beat(8)5
Avg EPS beat(8)-5.52%
EPS beat(12)5
Avg EPS beat(12)-23.88%
EPS beat(16)8
Avg EPS beat(16)-8.77%
Revenue beat(2)1
Avg Revenue beat(2)136.23%
Min Revenue beat(2)-55.74%
Max Revenue beat(2)328.2%
Revenue beat(4)3
Avg Revenue beat(4)161.51%
Min Revenue beat(4)-55.74%
Max Revenue beat(4)328.2%
Revenue beat(8)5
Avg Revenue beat(8)77.16%
Revenue beat(12)5
Avg Revenue beat(12)22.89%
Revenue beat(16)8
Avg Revenue beat(16)30.8%
PT rev (1m)0%
PT rev (3m)-34.08%
EPS NQ rev (1m)-3.55%
EPS NQ rev (3m)-4.07%
EPS NY rev (1m)0.13%
EPS NY rev (3m)0.93%
Revenue NQ rev (1m)-0.14%
Revenue NQ rev (3m)-11.67%
Revenue NY rev (1m)0%
Revenue NY rev (3m)7.04%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.89
P/FCF N/A
P/OCF N/A
P/B 6.71
P/tB 6.71
EV/EBITDA N/A
EPS(TTM)-6.08
EYN/A
EPS(NY)-5.43
Fwd EYN/A
FCF(TTM)-3.4
FCFYN/A
OCF(TTM)-3.39
OCFYN/A
SpS1.88
BVpS2.77
TBVpS2.77
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -33.57%
ROE -196.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-22.08%
ROA(5y)-18.68%
ROE(3y)-83.68%
ROE(5y)-56.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 59.71%
Cap/Sales 0.65%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.23
Quick Ratio 10.23
Altman-Z -1.09
F-Score4
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)132.56%
Cap/Depr(5y)131.66%
Cap/Sales(3y)3.46%
Cap/Sales(5y)4.25%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.15%
EPS Next Y-2.08%
EPS Next 2Y5.22%
EPS Next 3Y4.89%
EPS Next 5Y-4.65%
Revenue 1Y (TTM)282.17%
Revenue growth 3Y-38.84%
Revenue growth 5Y27.97%
Sales Q2Q%804.67%
Revenue Next Year441.71%
Revenue Next 2Y80.81%
Revenue Next 3Y57.97%
Revenue Next 5Y50.9%
EBIT growth 1Y5.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year9.55%
EBIT Next 3Y3.49%
EBIT Next 5YN/A
FCF growth 1Y-16.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.78%
OCF growth 3YN/A
OCF growth 5YN/A